Insulin detemir (100 U/mL) for Type 1 and Type 2 Diabetes Mellitus

Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF Link to the Evidence Summary: Evidence Summary on insulin glargine and detemir for type 1 and type 2 diabetes mellitus Link to appeals form here:  https://hta.doh.gov.ph/topic-nomination/ (stakeholders may submit appeals to hta@doh.gov.ph until 11 August 2022.)

Eribulin for Metastatic Soft Tissue Sarcoma (mSTS)

Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF Document link: Evidence summary on eribulin in the treatment of soft tissue sarcoma patients with previous treatment of two other chemotherapeutic agents for metastatic disease (Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via https://hta.doh.gov.ph/topic-nomination/.) Document Preview: